Trial Profile
Golimumab for Adherence in Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms GO FAR
- Sponsors Janssen Inc
- 21 Jul 2023 Status changed from active, no longer recruiting to completed.
- 30 May 2023 Planned End Date changed from 31 Aug 2023 to 18 Jul 2023.
- 30 May 2023 Planned primary completion date changed from 31 Aug 2023 to 18 Jul 2023.